It's high time to invest in educating patients about R&D

With clinical studies being postponed or interrupted amid a global pandemic, it might be tempting to press pause on patient engagement. That would be a mistake.

Instead, drug sponsors should seize the opportunity to invest in building capacity for patients to engage in R&D, so when the pandemic ebbs and the R&D engine re-engages, companies’ limited research dollars can go further...